EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC.
How has EGFR-NSCLC impacted people’s lives?
How will Disease transform EGFR-NSCLC Market?
“EGFR- NSCLC market size in 7MMwas USD 1,893 million in 2017”
Which biotechnical companies are developing EGFR-NSCLC drugs?
The dynamics of the EGFR-NSCLC market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in the development of drugs for EGFR-NSCLC.
Key players, such as Takeda, Yuhan Corporation/ Janssen Research & Development, Novartis, Janssen Research & Development, and others are involved in developing drugs for EGFR-NSCLC treatment market.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/